Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The conversation discusses hair regrowth progress using dutasteride 0.5 mg and oral minoxidil 2.5 mg over seven months. Users debate the effectiveness, with some noting slight improvements and others suggesting alternative treatments like finasteride.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

A 24-year-old is struggling with hair loss despite using treatments like dutasteride, oral minoxidil, RU58841, and considering a hair transplant. They are advised to continue medication, possibly increase dosages, and explore additional treatments like tretinoin and tacrolimus.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.

A user on Finasteride for 7-8 years reported unexpectedly high testosterone levels despite expecting lower levels due to age, with discussions on the impact of SHBG and suggestions to use boron to lower SHBG. Another user noted that Dutasteride significantly increased their testosterone and free testosterone levels.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The user shared progress on a 3-month hair loss treatment using dutasteride, minoxidil, and biotin, reporting no side effects. Others commented positively on the results and shared their own experiences.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

A user experienced significant hair regrowth using dutasteride without side effects, starting with finasteride and not using minoxidil or dermarolling. They attributed success to a unique genetic response to DHT blockers but did not share their full regimen, frustrating others.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.